CATEGORIES

31.01.2017

31.01.2017 09:00

ReFlow Therapeutics receives CTI Grant

ReFlow Therapeutics AG has been awarded a non-dilutive public grant of over CHF 823'000 from the Swiss Commission for Technology and Innovation. The funds will allow the Company to run their current project over the next 18 months.

27.01.2017

27.01.2017 13:20

Cellestia Biotech raises CHF 8 million seed financing

Cellestia Biotech AG, a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway, announced the final closing of its seed financing rounds securing a total of CHF 8 million in funding.

27.01.2017 12:50

Venture Capital: Switzerland among the Top European Countries

This week we presented the Swiss Venture Capital Report 2016. Data from other sources allow to compare Swiss investments with those of other countries.

26.01.2017

26.01.2017 16:52

ObsEva goes public

ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol “OBSV” on January 26, 2017. Today ObsEva CEO Ernest Loumaye will ring the Nasdaq stock market opening bell in celebration of the IPO.

26.01.2017 08:24

Johnson & Johnson to Acquire Actelion for $30 Billion With SpinOut of New R&D Company

Johnson & Johnson and Actelion Ltd. today announced that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion. Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company which will be listed on the SIX Swiss Exchange.

24.01.2017

24.01.2017 11:01

900 Millionen Franken für Startups

Innovative und stark wachsende Schweizer Startups haben im vergangenen Jahr 909 Millionen Franken eingesammelt; das sind 35 Prozent mehr als im Vorjahr. Gut die Hälfte des Geldes floss in Unternehmen aus dem Grossraum Lausanne. Besonders erfreulich entwickelte sich der ICT Sektor.

19.01.2017

19.01.2017 11:09

Biowatch SA raises CHF 1.2M in seed round

Biowatch SA has successfully closed the seed financing round with CHF 1.2M to finalise the development of their solution. The Lausanne based startup is developing a biometric recognition system that can be integrated any wearable for secure authentication.

Show All

Events

09.03.2017 18:00 - 22:00

Swiss Fintech Awards Night The Dolder Grand

MEET US

Show All

Trainings

7th - 22nd March 2017

CTI Entrepreneurship - Business Growth - Module 4 EPFL Innovation Park - Lausanne

Top viewed

Show All

Video

Tweets

Principal

Partners

Contributors